Skip to main content
SpringerLink
Log in

Biomarkers in Heart Failure: ST2

  • Chapter
  • First Online:
Cardiac Biomarkers

  • 1191 Accesses

Abstract

Biomarkers have emerged as indispensable tools for diagnosis and prognosis in a variety of cardiovascular diseases, and several are now considered standard of care. New markers are constantly being developed, but very few are able to significantly improve upon already-established markers. ST2 is a marker of cardiomyocyte stress and fibrosis which provides incremental value to natriuretic peptides for risk stratification in heart failure. Based upon the totality of data, measurement of ST2 is now recommended for additive risk stratification in patients with acute or ambulatory heart failure in the 2013 ACCF/AHA Guidelines. Looking forward, ST2 levels may be useful for tailoring medical therapy and to predict ventricular reverse remodeling. This chapter provides an up-to-date overview of ST2 as a marker of heart failure, and provides illustrative clinical cases into the application of ST2 now and in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dieplinger B, Januzzi Jr JL, Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta. 2009;409:33–40.

    Article  CAS  PubMed  Google Scholar 

  3. Bayes-Genis A, Zamora E, de Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail. 2013;19:768–7.

    Article  CAS  PubMed  Google Scholar 

  4. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013;165:995–9.

    Article  CAS  PubMed  Google Scholar 

  5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  PubMed  Google Scholar 

  6. Januzzi Jr JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607–13.

    Article  CAS  PubMed  Google Scholar 

  7. Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem. 2011;57:874–82.

    Article  CAS  PubMed  Google Scholar 

  8. Bayes-Genis A, De Antonio M, Galan A, et al. Combined use of high-sensitivity ST2 and NT-proBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012;14:32–8.

    Article  CAS  PubMed  Google Scholar 

  9. Ky B, French B, Mccloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180–7.

    Article  PubMed  Google Scholar 

  10. Ky B, French B, Levy WC, Sweitzer NK. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lupón J, de Antonio M, Galán A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88:234–43.

    Article  PubMed  Google Scholar 

  12. Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One. 2014;9:e85466.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14:732–8.

    Article  PubMed  Google Scholar 

  14. Llibre C, Zamora E, Caballero A, et al. The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. Biomarkers. 2016;21(3):225–32.

    Article  CAS  PubMed  Google Scholar 

  15. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243–50.

    Article  CAS  PubMed  Google Scholar 

  16. Lupón J, Gaggin HK, de Antonio M, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score. Int J Cardiol. 2015;184:337–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Heart Failure Unit, Heart Institute, Hospital Universitari, Germans Trias i Pujol, Badalona, Barcelona, Spain

    Antoni Bayes-Genis MD, PhD

  2. Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    Antoni Bayes-Genis MD, PhD

  3. Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

    Josep Lupón MD, PhD

  4. Heart Failure Unit, Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    Josep Lupón MD, PhD

Authors
  1. Antoni Bayes-Genis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep Lupón MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoni Bayes-Genis MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Medicine, University of California San Diego Division of Cardiovascular Medicine, La Jolla, California, USA

    Alan S. Maisel

  2. Cardiology Department, Mayo Clinic Cardiology Department, ROCHESTER, Minnesota, USA

    Allan S. Jaffe

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bayes-Genis, A., Lupón, J. (2016). Biomarkers in Heart Failure: ST2. In: Maisel, A., Jaffe, A. (eds) Cardiac Biomarkers. Springer, Cham. https://doi.org/10.1007/978-3-319-42982-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42982-3_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42980-9

  • Online ISBN: 978-3-319-42982-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation